SARS-CoV-2, Influenza, RSV
Conditions
Keywords
mRNA-1230 Vaccine, mRNA-1045 Vaccine, SARS-CoV-2 Vaccine, Influenza Vaccine, RSV Vaccine, Coronavirus, Virus Diseases, Messenger RNA, COVID-19, COVID-19 Vaccine, Moderna
Brief summary
The primary goal of this study is to evaluate the safety and reactogenicity of multi-component vaccines mRNA-1045 (Influenza and RSV) and mRNA-1230 (influenza, RSV, and SARS-CoV-2) compared with mRNA-1010 (influenza), mRNA-1345 (RSV), and mRNA-1273.214 (SARS-CoV-2) vaccines in healthy older participants.
Interventions
BIOLOGICALmRNA-1010
Sterile liquid for injection
BIOLOGICALmRNA-1345
Sterile liquid for injection
BIOLOGICALmRNA-1273.214
Sterile liquid for injection
BIOLOGICALmRNA-1045
Formulation for injection
BIOLOGICALmRNA-1230
Formulation for injection
Sponsors
ModernaTX, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
All participants will be unblinded at Day 29 (1 month following study injection) to seek immunization with licensed influenza and/or SARS-CoV-2 vaccines, outside of the study, per local standard of care.
Eligibility
Sex/Gender
ALL
Age
50 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
* Investigator assessment that participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures. * Body mass index of 18 to 35 kilograms/square meter (kg/m\^2) (inclusive) at the Screening Visit(s). * For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding. * Fully vaccinated for COVID-19 with an approved primary series according to the locally authorized or approved regimen. The most recent COVID-19 vaccine (primary series or booster) must be ≥120 days before (or less per local guidance) Day 1.
Exclusion criteria
* Acutely ill or febrile (temperature ≥38.0°Celsius/\[100.4°Fahrenheit\]) 72 hours before or at the Screening Visit or Day 1. Participants meeting this criterion may be rescheduled within the 28-day screening window for re-evaluation and will retain their initially assigned participant number. * Any medical, psychiatric, or occupational condition, including reported history of drug or alcohol abuse, that, in the opinion of the investigator, might pose additional risk due to participation in the study or could interfere with the interpretation of study results. * Has received systemic immunosuppressants or immune-modifying drugs for \>14 days in total within 6 months before screening (for corticosteroids ≥10 milligrams (mg)/day of prednisone or equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study. * Received or plans to receive any vaccine authorized or approved by a local health agency ≤28 days before study injections (Day 1) or within 28 days after the study injection. * Received a licensed seasonal influenza vaccine or any other investigational influenza or RSV vaccine within ≤180 days before Day 1. * Tested positive for influenza or RSV by local health authority-approved testing methods within ≤180 days before Day 1. * Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, as defined by the United States Center for Disease Control (CDC) or the European Centre for Disease Prevention and Control as a high risk (close contact) of a COVID-19 case or known history of SARS-CoV-2 infection within the past 90 days before Day 1. * Donated ≥450 mL of blood products within 28 days before the Screening Visit or plans to donate blood products during the study. Note: Other inclusion and
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs) | Up to Day 8 (7 days post vaccination) |
| Number of Participants with Unsolicited Adverse Events (AEs) | Up to Day 29 (28 days post vaccination) |
| Number of Participants with Medically-Attended AEs (MAAEs) | Day 1 through Day 361 |
| Number of Participants with Adverse Events of Special Interest (AESIs) | Day 1 through Day 361 |
| Number of Participants with Serious Adverse Events (SAEs) | Day 1 through Day 361 |
| Number of Participants with AEs Leading to Discontinuation | Day 1 through Day 361 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Influenza: Percentage of Participants with Seroconversion as Measured by HAI Assay | Baseline (Day 1) to Day 29 | Seroconversion is defined as a Day 29 titer ≥1:40 if baseline is \<1:10 or a 4-fold or greater rise if baseline is ≥1:10 in anti-HA antibodies measured by HAI assay. |
| Change From Baseline in Geometric Mean Titer (GMT) as Measured by Hemagglutination Inhibition (HAI) Assay at Day 29 | Baseline (Day 1), Day 29 | — |
| RSV: Percentage of Participants with Seroresponse as Measured by RSV Neutralization Assay | Baseline (Day 1) to Day 29 | Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥LLOQ or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by RSV neutralization assay. |
| SARS-CoV-2: Percentage of Participants with Seroresponse as Measured by PsVNA (or Binding Antibody Assay) | Baseline (Day 1) to Day 29 | Seroresponse is defined as a Day 29 titer ≥4-fold if baseline is ≥lower limit of quantification (LLOQ) or ≥4\*LLOQ if baseline titer is \<LLOQ in nAb titers measured by PsVNA (or binding antibody assay). |
| Change From Baseline in GMT as Measured by Pseudovirus Neutralization Assay (PsVNA) (or Binding Antibody Assay) at Day 29 | Baseline (Day 1), Day 29 | — |
| Change From Baseline in GMT as Measured by Microneutralization Assay at Day 29 | Baseline (Day 1), Day 29 | — |
| Change From Baseline in Geometric Mean Fold-Rise (GMFR) as Measured by HAI Assay at Day 29 | Baseline (Day 1), Day 29 | — |
| Change From Baseline in GMFR as Measured by PsVNA (or Binding Antibody Assay) at Day 29 | Baseline (Day 1), Day 29 | — |
| Change From Baseline in GMFR as Measured by Microneutralization Assay at Day 29 | Baseline (Day 1), Day 29 | — |
Countries
Australia, United Kingdom, United States
Outcome results
None listed